Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 33.04M P/E - EPS this Y - Ern Qtrly Grth -
Income -80.79M Forward P/E - EPS next Y - 50D Avg Chg -16.00%
Sales 5.86M PEG - EPS past 5Y - 200D Avg Chg 129.00%
Dividend N/A Price/Book 0.23 EPS next 5Y - 52W High Chg -64.00%
Recommedations - Quick Ratio 2.09 Shares Outstanding 12.22M 52W Low Chg 21,329.00%
Insider Own 0.57% ROA -9.55% Shares Float 8.65M Beta -14.37
Inst Own 29.06% ROE -63.17% Shares Shorted/Prior -/- Price 3.00
Gross Margin 75.26% Profit Margin - Avg. Volume 89,258 Target Price -
Oper. Margin -383.59% Earnings Date - Volume 967 Change 0.00%
About RELIEF THERAPEUTICS HOLDING AG

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.

RELIEF THERAPEUTICS HOLDING AG News
03/27/24 RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
03/22/24 Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
03/22/24 Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
02/28/24 Relief Therapeutics Renews CHF 50 million Share Subscription Facility
12/05/23 Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
11/22/23 Relief Therapeutics Announces CEO Transition
10/10/23 Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
09/15/23 Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
09/01/23 Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08/30/23 Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
07/19/23 Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
12:30 AM Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE(R) in the Middle East
12:30 AM RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
06/20/23 RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
06/16/23 RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
05/15/23 Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
05/12/23 Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
05/03/23 Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
05/01/23 Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
04/28/23 Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
RLFTF Chatroom

User Image Thomas105 Posted - 3 days ago

$RLFTF Why aren't there more efforts on the part of Relief to promote Aviptadil? In my opinion, this question must be asked and answered satisfactorily. Next Friday April 26th in Geneva EGM.

User Image HOID Posted - 5 days ago

$RLFTF $NRXP https://wsvn.com/news/local/miami-dade/miami-beach-doctor-recovering-from-covid-19-after-taking-new-drug/

User Image HOID Posted - 5 days ago

$NRXP $RLFTF https://www.jcvaonline.com/article/S1053-0770(24)00113-7/fulltext

User Image _nic Posted - 2 weeks ago

@Joesh82 hcw is worth shit $NRXP $RLFTF $ACER

User Image meowmeowmeowmeow Posted - 2 weeks ago

$RLFTF Capital Reduction by Reduction of Nominal Value The Board proposes to reduce the nominal value of the Company's share capital from CHF 56'163'348.00 to CHF 1'404'083.70 by reducing the nominal value of each share from CHF 4.00 to CHF 0.10. This technical adjustment comes as the share currently quotes at a price below its par value. This situation presents practical implications, including limiting the Company's ability to raise capital. The number of outstanding shares, as well as shareholders' financial and patrimonial rights, will not be affected by the reduction in par value. The modification of the share capital shall render the capital band provisions under the Articles of Association void.

User Image cyber10 Posted - 2 weeks ago

$RLFTF Who's buying this turd?

User Image HOID Posted - 2 weeks ago

$RLFTF

User Image flybyme Posted - 2 weeks ago

$RLFTF another low today day.Ram are you there????

User Image QLBatiatus Posted - 3 weeks ago

$RLFTF Where is Ramalamadingdong these days? I hear he and Nader Pourhassan over from the old CYDY days opened a falafel stand together. They need money to run more clinical trials

User Image Prospecteur Posted - 3 weeks ago

$RLFTF to answer PENNYSTOCK, yes you are right, in 2020, this company had a lot of shareholders but the managers of the company missed the boat. They scared away shareholders by diluting at an infernal pace, not to mention reverse splits. we have been managed by lying and crooked leaders. They ruined excellent shareholders and made questionable choices like buying 3rd rate companies. They are responsible for their failure. a rotten board of directors. as I always thought RLFTF is a bogus company of GEM, RAM and Mrs. LOCK are the puppets of GEM.

User Image Pennywise77 Posted - 03/31/24

$NRXP does Dr J still pump on here?? Miss the $rlftf days, first stock I ever bought long,.I was.hooked, remember it went from 4 cents to 96 cents in two trading days? We had a discord fam that was thick as thieves,planned a Vegas trip and all, good Ole days!!

User Image Pennywise77 Posted - 03/30/24

$RLFTF was the first stock I went long on, back in 2020 when I debuted in stock market, lost a ton of money and valuable lesson, always take profit and never trust the management! Me and a ton of others from our discord lost alot of $$, we were all drinking the juice and believing everything, we had a Vegas trip planned, we believed in our hearts that we would get fda eua approval for aviptadil, and all got played! And I come back and see it's all whole new group of ppl now going thru round two! Wish everyone the best of luck, I am staying away from penny stocks these days, way too risky!! Happy Easter 🐰 all my fella bulls!! This is only the bullginning!

User Image Pennywise77 Posted - 03/30/24

@Fundamental_illness hey bro, I'm still in the market, but had to get away from $nrxp $rlftf Dr Javitt started contacting me with threats of lawsuits because I was speaking the truth, I see he has a whole new group of Investers believing his BS, lol, hope all is well, happy easter!!

User Image Humblehustle Posted - 03/29/24

@Johnsmilewin it was the same ordeal when they were attached to $RLFTF a lawsuit against NeuroRx, and its Chief Executive Officer, Dr. Jonathan Javitt, for multiple breaches of the Collaboration Agreement between Relief and NeuroRx relating to the development and commercialization of RLF-100™ (aviptadil). The complaint was filed in the Supreme Court of the State of New York in Manhattan. Investors got 🔩.

User Image the_franz Posted - 03/27/24

$RLFTF So, this is a holding company held by GEM now? Would there be any non-financial professionals left in BoD? Is this all even legal? Owning approx. 25% of a company and owning 3 seats and the ability to issue shares for CHF 50m in the SSF within the capital band, i.e. raise its ownership without shareholders' consent? No time for reentry. To all existing shareholders: organise and decline this nonsense and demand answers! https://relieftherapeutics.com/newsblog-detail/?newsID=2733327

User Image OleHaw Posted - 03/26/24

@Prospecteur me walking up to my $RLFTF bag

User Image QLBatiatus Posted - 03/26/24

$RLFTF The only Relief investors get when they buy this worthless sham of a company’s shares is Relief from their hard earned money. STAY AWAY

User Image Prospecteur Posted - 4 weeks ago

$RLFTF the former shareholders were robbed and betrayed by the president and members of the board of directors. They unscrupulously ruined those who financed the studies. we know that a friend at RAM the chairman of the board of directors was charged with fraud and imprisoned during his time with another company

User Image Prospecteur Posted - 4 weeks ago

$RLFTF Mrs. LOCK's big ass continues to impoverish her shareholders, let's remember the reverse split 400 for 1 so this title in reality is only worth 0.004. It’s a pile of dung. during her election to the board of directors of the big ass Madame LOCK the sp was 0.075. Now it's not even worth half a cent. a muck team.

User Image HOID Posted - 1 month ago

$NRXP $RLFTF https://www.ntd.com/fda-settles-ivermectin-case-agrees-to-remove-controversial-stop-it-post_981178.html Why didn’t the Doctor sue the NIH for sabotaging the Aviptadil trial and hurting his reputation?

User Image flybyme Posted - 1 month ago

$RLFTF funny every time i write sime news comes hahah

User Image the_franz Posted - 1 month ago

$RLFTF Oh look. It's alive! First clear sign of a shift to B2B model. No clue if deal is good, but having reached $1m in 2024 and now receiving just mid-teen royalties sounds not that good to me - especially if $ETON expects "Estimated peak sales of more than $10 million annually" (according to their PR). So basically no gain in revenue for Relief. 🤔 Some more info for $ETON shareholders regarding RLF-OD32. It is most likely Sapropterin in a liquid formulation, see (pending) patent here: https://patents.google.com/patent/US20230241069A1/en

User Image cyber10 Posted - 1 month ago

$RLFTF More smoke and mirrors to reel in new suckers https://relieftherapeutics.com/newsblog-detail/?newsID=2730235

User Image 27Amberjack Posted - 1 month ago

$RLFTF He is sipping expensive wine in his new Ferrari. No time for RLFTF.

User Image flybyme Posted - 1 month ago

$RLFTF Ram are you there, so many lost money here, talk to us like JJ does.Give us hope

User Image flybyme Posted - 1 month ago

$RLFTF another year low.

User Image SIXswiss Posted - 1 month ago

$ZOM my stonks to stay from $TOON $RLFTF $MULN $FSRN Wake me up in 5 years and see if they still exist.

User Image the_franz Posted - 1 month ago

$RLFTF William Blair analyses Zevra and rates Olpruva as "becoming at least a $200 million product". I still don't understand the bullshit deal Relief negotiated with Acer prior to the merger but well...

User Image cyber10 Posted - 1 month ago

$RLFTF 👇 Therapeutics, anyone?

User Image soup_g9 Posted - 1 month ago

$RLFTF Whenever I feel like puking I think of how I stupidly invested in this. Gets the job done quicker that way.